NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Roche Holding AG (OTCQX: RHHBY)

 
RHHBY Technical Analysis
5
As on 3rd Jul 2025 RHHBY STOCK Price closed @ 40.51 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 33.81 & Strong Buy for SHORT-TERM with Stoploss of 35.37 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

RHHBYSTOCK Price

Open 40.70 Change Price %
High 40.70 1 Day -0.68 -1.65
Low 40.38 1 Week 0.47 1.17
Close 40.51 1 Month -0.20 -0.49
Volume 71684 1 Year 2.65 7.00
52 Week High 43.70 | 52 Week Low 29.26
 
OTCQX USA Most Active Stocks
KRRGF 4.83 2.33%
FCUUF 0.52 -20.00%
NCPL 6.70 -20.71%
CRLBF 0.51 -15.00%
ETHE 21.32 -1.20%
GBTC 86.07 -0.42%
GSVRF 0.18 50.00%
EMHTF 0.04 33.33%
SHIEF 0.04 0.00%
GTBIF 8.95 14.74%
 
OTCQX USA Top Gainers Stocks
LGCP 0.09 200.00%
NWINF 1.12 111.32%
VVCIF 0.02 100.00%
ARSMF 0.24 71.43%
PXCLF 0.05 66.67%
CBULF 0.08 60.00%
PKKFF 0.03 50.00%
GSVRF 0.18 50.00%
COGZF 0.85 39.34%
OGNRF 1.41 38.24%
 
OTCQX USA Top Losers Stocks
AIXN 0.10 -80.39%
AKOWF 0.05 -76.19%
CANSF 0.02 -66.67%
PBTHF 0.41 -41.43%
BRST 0.10 -41.18%
WPNDF 0.09 -40.00%
TRCK 0.12 -36.84%
JRSS 0.02 -33.33%
TNYYF 0.02 -33.33%
KOREF 0.02 -33.33%
 
 
RHHBY
Daily Charts
RHHBY
Intraday Charts
Whats New @
Bazaartrend
RHHBY
Free Analysis
 
RHHBY Important Levels Intraday
RESISTANCE41.13
RESISTANCE40.93
RESISTANCE40.81
RESISTANCE40.68
SUPPORT40.34
SUPPORT40.21
SUPPORT40.09
SUPPORT39.89
 
RHHBY Forecast July 2025
4th UP Forecast47.83
3rd UP Forecast45.48
2nd UP Forecast44.03
1st UP Forecast42.58
1st DOWN Forecast38.44
2nd DOWN Forecast36.99
3rd DOWN Forecast35.54
4th DOWN Forecast33.19
 
RHHBY Weekly Forecast
4th UP Forecast43.94
3rd UP Forecast42.84
2nd UP Forecast42.16
1st UP Forecast41.48
1st DOWN Forecast39.54
2nd DOWN Forecast38.86
3rd DOWN Forecast38.18
4th DOWN Forecast37.08
 
RHHBY Forecast2025
4th UP Forecast68.95
3rd UP Forecast59.83
2nd UP Forecast54.19
1st UP Forecast48.55
1st DOWN Forecast32.47
2nd DOWN Forecast26.83
3rd DOWN Forecast21.19
4th DOWN Forecast12.07
 
 
RHHBY Other Details
Segment EQ
Market Capital 340336410624.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
RHHBY Address
RHHBY
 
RHHBY Latest News
 
Your Comments and Response on Roche Holding AG
 
RHHBY Business Profile
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick's samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. Address: Konzern Hauptsitz, Basel, Switzerland, 4070
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service